EXACT THERAPEUTICS AS presents data from two patients with liver metastases of colorectal cancer origin treated with ACT in the clinical Phase I ACTIVATE trial. The presented radiological results from these two patients suggest an improved response to standard of care chemotherapy in the tumours that are exposed to ACT treatment. This aligns well with the preclinical evidence that ACT treatment can enhance the response to several chemotherapies in different cancer models.

Based on the initial clinical results, ACT treatment does not add to the safety or tolerability burden on patients. No adverse events considered related to the ACT treatment were seen in these two patients when ACT was combined with standard of care chemotherapy. So far, seven patients have been enrolled in the study and encouraging insights have been gained from these patients.

EXACT Therapeutics is now in the process of completing the dose-escalation part of the study and will thereafter randomise up to 20 patients to two dose levels of ACT in an expansion part of the Phase I ACTIVATE trial.